Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00154362
Status:
COMPLETED
Last Update Posted:
2011-11-24
First Post:
2005-09-08
Brief Title:
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mgDay as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Multi-center Randomized Double-blind Cross-over Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine po 300-1200 mgDay as Adjuvant Therapy for Impulsivity and Aggressive Behavior in Conduct Disorders in Adolescents
Status:
COMPLETED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior This study will investigate the efficacy a safety of oxcarbazepine in the treatment of adolescents with conduct disorder
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None